Letter to the Editor: Central nervous system relapse rate and dose intensification in poor risk metastatic germ cell tumours—A comment on: ‘Patterns of relapse in poor prognosis germ cell tumours in the GETUG-13 trial: Implications for the assessment of brain metastases.’ by Loriot and colleagues
Publication date: May 2018 Source:European Journal of Cancer, Volume 95 Author(s): Constantine Alifrangis, Peter Wilson, Jonathan Shamash
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου